Surgical Management of Germline Gastrointestinal Stromal Tumor.
GIST
Mutation
Surgery
Tyrosine kinase inhibitor
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
06
02
2023
accepted:
06
04
2023
medline:
7
7
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
ppublish
Résumé
Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and usually results from a sporadic mutation in KIT or, less frequently, platelet-derived growth factor alpha (PDGFRA). Rarely, a germline mutation in the KIT, PDGFRA, succinate dehydrogenase (SDH), or neurofibromatosis 1 (NF1) gene is responsible for GIST. These tumors are found in the stomach (PDGFRA and SDH), small bowel (NF1), or a combination of both (KIT). There is a need to improve care for these patients regarding genetic testing, screening, and surveillance. Since most GISTs due to a germline mutation do not respond to tyrosine kinase inhibitors, the role of surgery is critical, especially when considering germline gastric GIST. However, in contrast to the established recommendation for prophylactic total gastrectomy in cadherin 1 (CDH1) mutation carriers once they reach adulthood, there are no formal guidelines as to the timing or extent of surgical resection for patients who are either carriers of a germline GIST mutation causing gastric GIST or have already developed gastric GIST(s). Surgeons must balance treating what is often multicentric, yet initially indolent disease with the chance of cure and the complications associated with total gastrectomy. Here, we consider the major issues in performing surgery in patients with germline GIST and illustrate the principles with a previously unreported patient harboring a germline KIT 579 deletion.
Identifiants
pubmed: 37115371
doi: 10.1245/s10434-023-13519-y
pii: 10.1245/s10434-023-13519-y
doi:
Substances chimiques
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
Receptor, Platelet-Derived Growth Factor alpha
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4966-4974Subventions
Organisme : NIH HHS
ID : R01 CA102613
Pays : United States
Organisme : NIH HHS
ID : T32 CA251063
Pays : United States
Organisme : NIH HHS
ID : R01 CA102613
Pays : United States
Organisme : NIH HHS
ID : T32 CA251063
Pays : United States
Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med. 2012;63:247–58. https://doi.org/10.1146/annurev-med-043010-091813 .
doi: 10.1146/annurev-med-043010-091813
pubmed: 22017446
Ricci R. Syndromic gastrointestinal stromal tumors. Hered Cancer Clin Pract. 2016;14:15. https://doi.org/10.1186/s13053-016-0055-4 .
doi: 10.1186/s13053-016-0055-4
pubmed: 27437068
pmcid: 4950812
Fornasarig M, Gasparotto D, Foltran L, et al. A novel kindred with familial gastrointestinal stromal tumors caused by a rare KIT germline mutation (N655K): clinico-pathological presentation and TKI sensitivity. J Pers Med. 2020. https://doi.org/10.3390/jpm10040234 .
doi: 10.3390/jpm10040234
pubmed: 33212994
pmcid: 7711910
Brodey A, Kounnis V, Hawkes L, Jones RL, McVeigh TP, Cojocaru E. KIT-associated familial GIST syndrome: response to tyrosine kinase inhibitors and implications for risk management. Oncologist. 2022;27(8):615–20. https://doi.org/10.1093/oncolo/oyac120 .
doi: 10.1093/oncolo/oyac120
pubmed: 35791894
pmcid: 9355806
Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology. 2001;120(1):210–5. https://doi.org/10.1053/gast.2001.20880 .
doi: 10.1053/gast.2001.20880
pubmed: 11208730
Wali GN, Halliday D, Dua J, Ieremia E, McPherson T, Matin RN. Cutaneous hyperpigmentation and familial gastrointestinal stromal tumour associated with KIT mutation. Clin Exp Dermatol. 2019;44(4):418–21. https://doi.org/10.1111/ced.13757 .
doi: 10.1111/ced.13757
pubmed: 30280421
Bachet JB, Landi B, Laurent-Puig P, et al. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. Eur J Cancer. 2013;49(11):2531–41. https://doi.org/10.1016/j.ejca.2013.04.005 .
doi: 10.1016/j.ejca.2013.04.005
pubmed: 23648119
Belinsky MG, Rink L, von Mehren M. Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors. Front Oncol. 2013;3:117. https://doi.org/10.3389/fonc.2013.00117 .
doi: 10.3389/fonc.2013.00117
pubmed: 23730622
pmcid: 3656383
Boikos SA, Pappo AS, Killian JK, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic. JAMA Oncol. 2016;2(7):922–8. https://doi.org/10.1001/jamaoncol.2016.0256 .
doi: 10.1001/jamaoncol.2016.0256
pubmed: 27011036
pmcid: 5472100
MacFarlane J, Seong KC, Bisambar C, et al. A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: beyond phaeochromocytoma and paraganglioma. Clin Endocrinol (Oxf). 2020;93(5):528–38. https://doi.org/10.1111/cen.14289 .
doi: 10.1111/cen.14289
pubmed: 32686200
Manley PN, Abu-Abed S, Kirsch R, et al. Familial PDGFRA-mutation syndrome: somatic and gastrointestinal phenotype. Hum Pathol. 2018;76:52–7. https://doi.org/10.1016/j.humpath.2018.02.014 .
doi: 10.1016/j.humpath.2018.02.014
pubmed: 29486293
Gopie P, Mei L, Faber AC, Grossman SR, Smith SC, Boikos SA. Classification of gastrointestinal stromal tumor syndromes. Endocr Relat Cancer. 2018;25(2):R49-r58. https://doi.org/10.1530/erc-17-0329 .
doi: 10.1530/erc-17-0329
pubmed: 29170162
Neppala P, Banerjee S, Fanta PT, et al. Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. Cancer Metastasis Rev. 2019;38(3):525–35. https://doi.org/10.1007/s10555-019-09818-0 .
doi: 10.1007/s10555-019-09818-0
pubmed: 31773431
pmcid: 6903702
Elston MS, Sehgal S, Dray M, et al. A duodenal SDH-deficient gastrointestinal stromal tumor in a patient with a germline SDHB mutation. J Clin Endocrinol Metab. 2017;102(5):1447–50. https://doi.org/10.1210/jc.2017-00165 .
doi: 10.1210/jc.2017-00165
pubmed: 28324028
Nannini M, Rizzo A, Indio V, Schipani A, Astolfi A, Pantaleo MA. Targeted therapy in SDH-deficient GIST. Ther Adv Med Oncol. 2021;13:17588359211023278. https://doi.org/10.1177/17588359211023278 .
doi: 10.1177/17588359211023278
pubmed: 34262616
pmcid: 8246492
Ben-Ami E, Barysauskas CM, von Mehren M, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016;27(9):1794–9. https://doi.org/10.1093/annonc/mdw228 .
doi: 10.1093/annonc/mdw228
pubmed: 27371698
pmcid: 6279099
Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv68–78. https://doi.org/10.1093/annonc/mdy095 .
doi: 10.1093/annonc/mdy095
pubmed: 29846513
Mandelker D, Marra A, Mehta N, et al. Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations. NPJ Precis Oncol. 2023;7(1):1. https://doi.org/10.1038/s41698-022-00342-z .
doi: 10.1038/s41698-022-00342-z
pubmed: 36593350
pmcid: 9807588
Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62. https://doi.org/10.1038/ajg.2014.435 .
doi: 10.1038/ajg.2014.435
pubmed: 25645574
pmcid: 4695986
Gamble LA, Heller T, Davis JL. Hereditary diffuse gastric cancer syndrome and the role of CDH1: a review. JAMA Surg. 2021;156(4):387–92. https://doi.org/10.1001/jamasurg.2020.6155 .
doi: 10.1001/jamasurg.2020.6155
pubmed: 33404644
Janeway KA, Weldon CB. Pediatric gastrointestinal stromal tumor. Semin Pediatr Surg. 2012;21(1):31–43. https://doi.org/10.1053/j.sempedsurg.2011.10.003 .
doi: 10.1053/j.sempedsurg.2011.10.003
pubmed: 22248968
Pappo AS, Janeway K, Laquaglia M, Kim SY. Special considerations in pediatric gastrointestinal tumors. J Surg Oncol. 2011;104(8):928–32. https://doi.org/10.1002/jso.21868 .
doi: 10.1002/jso.21868
pubmed: 22069178
Weldon CB, Madenci AL, Boikos SA, et al. Surgical management of wild-type gastrointestinal stromal tumors: a report from the national institutes of health pediatric and wildtype GIST clinic. J Clin Oncol. 2017;35(5):523–8. https://doi.org/10.1200/jco.2016.68.6733 .
doi: 10.1200/jco.2016.68.6733
pubmed: 28029307
Vos EL, Salo-Mullen EE, Tang LH, et al. Indications for total gastrectomy in CDH1 mutation carriers and outcomes of risk-reducing minimally invasive and open gastrectomies. JAMA Surg. 2020;155(11):1050–7. https://doi.org/10.1001/jamasurg.2020.3356 .
doi: 10.1001/jamasurg.2020.3356
pubmed: 32997132
Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS. Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery. 2011;149(3):347–55. https://doi.org/10.1016/j.surg.2010.07.005 .
doi: 10.1016/j.surg.2010.07.005
pubmed: 20719348
Yoo C, Ryu MH, Kang BW, et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol. 2010;28(9):1554–9. https://doi.org/10.1200/JCO.2009.26.5785 .
doi: 10.1200/JCO.2009.26.5785
pubmed: 20177019
Lubberman FJE, Gelderblom H, Wilmer CM, et al. Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy? Br J Clin Pharmacol. 2017;83(10):2312–4. https://doi.org/10.1111/bcp.13333 .
doi: 10.1111/bcp.13333
pubmed: 28677263
pmcid: 5595978
Forde PM, Cochran RL, Boikos SA, et al. Familial GI stromal tumor with loss of heterozygosity and amplification of mutant KIT. J Clin Oncol. 2016;34(3):e13–6. https://doi.org/10.1200/jco.2013.51.6633 .
doi: 10.1200/jco.2013.51.6633
pubmed: 24868028
Jones DH, Caracciolo JT, Hodul PJ, Strosberg JR, Coppola D, Bui MM. Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutation. Cancer Control. 2015;22(1):102–8. https://doi.org/10.1177/107327481502200113 .
doi: 10.1177/107327481502200113
pubmed: 25504284
Kleinbaum EP, Lazar AJ, Tamborini E, et al. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. Int J Cancer. 2008;122(3):711–8. https://doi.org/10.1002/ijc.23137 .
doi: 10.1002/ijc.23137
pubmed: 17943734
Lasota J, Miettinen M. A new familial GIST identified. Am J Surg Pathol. 2006;30(10):1342. https://doi.org/10.1097/01.pas.0000213364.56498.3b .
doi: 10.1097/01.pas.0000213364.56498.3b
pubmed: 17001171
Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30(4):477–89. https://doi.org/10.1097/00000478-200604000-00008 .
doi: 10.1097/00000478-200604000-00008
pubmed: 16625094
Tarn C, Merkel E, Canutescu AA, et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res. 2005;11(10):3668–77. https://doi.org/10.1158/1078-0432.Ccr-04-2515 .
doi: 10.1158/1078-0432.Ccr-04-2515
pubmed: 15897563